BioNTech, the German biotech that partnered with Pfizer to develop the first COVID-19 vaccine to earn the FDA's emergency use authorization, is now using mRNA to tackle another disease: malaria.
The biotech plans to start testing its malaria vaccine in clinical trials by the end of 2022, according to a July 26 news release.
As a part of its efforts to combat disease and death from malaria, BioNTech is also evaluating sustainable mRNA vaccine production capacities in Africa.
"The response to the pandemic has shown that science and innovation can transform people's lives when all key stakeholders work together towards a common goal. We are committed to bringing our innovations to those who need them most," BioNTech CEO Ugur Sahin, MD, PhD, said in the news release.